MedTrace Logo

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

NCT04142125 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2023-09-26

No results posted yet for this study

Summary

CATIS-ICAD is a clinical pilot study in which patients who have had a recent ischemic stroke, that is a stroke caused by a blood clot or a narrowing of the blood vessels in the brain due to the build up of plaque, will be randomly assigned to receive either low-dose rivaroxaban + aspirin or aspirin alone.

Conditions

Interventions

DRUG

Rivaroxaban 2.5 Mg Oral Tablet bid

Pts will receive rivaroxaban + aspirin

DRUG

Acetylsalicyclic acid 81 mg tablet qd

Pts will receive ASA

Sponsors & Collaborators

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Kanjana S. Perera, MD, FRCPC · Hamilton Health Sciences Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2023-09-18
Completion
2023-09-18

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04142125 on ClinicalTrials.gov